Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01226628 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01226628 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 39 participants.
The verdict
NCT01226628, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The main purpose of this study to evaluate the safety and tolerability of CNTO 2476 administered subretinally (beneath the retina) using the iTrack Model 275 micro catheter in patients with visual acuity (acuteness or clearness of vision) impairment associated with the geographic atrophy (GA: partial or complete wasting away of retinal layer below the retina) manifestation of age-related macular degeneration (AMD: medical condition which usually affects older adults and results in a loss of vision in the center of the visual field \[the macula\] because of damage to the retina).
Interventions
- BIOLOGICAL CNTO 2476
- PROCEDURE iTrack Model 275 micro catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-10-21 |
| Est. Completion | 2017-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01226628
The ClinicalTrials.gov registry entry for NCT01226628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CNTO 2476 is the first listed.
NCT01226628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01226628 about?
NCT01226628 is a clinical study titled "A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration". The main purpose of this study to evaluate the safety and tolerability of CNTO 2476 administered subretinally (beneath the retina) using the iTrack Model 275 micro catheter in patients with visual acuity (acuteness or clearness of vision) impairment associated with the geographic atrophy (GA: partia...
What is the current status of trial NCT01226628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2010-10-21. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT01226628?
The interventions under investigation include: CNTO 2476 (BIOLOGICAL), iTrack Model 275 micro catheter (PROCEDURE).
Who is sponsoring clinical trial NCT01226628?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.